Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...
Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan ...
Rising awareness of sleep-related breathing disorders, advanced home care adoption, and improved diagnostic infrastructure are driving market expansion across major regions.Austin, Oct. 22, 2025 ...
Ensifentrine significantly improved lung function after 12 weeks in patients with moderate to severe COPD with and without ...
Most patients with persistent pulmonary symptoms after recovering from mild to moderate COVID-19 infection have normal ...
This approach offers an excellent negative predictive value.1 However, its specificity is poor and there is an increasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback